George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension.

• Results from two Phase III trials testing multi-mechanism, triple combination of existing best-in-class medicines in novel low and ultra-low dose pills
• Combination pill significantly reduced blood pressure and improved control rates vs dual therapy or placebo, with good tolerability and no increase in adverse event withdrawals
• Results also presented from first trial in Africa evaluating a low-dose triple combination pill as initial or early therapy for hypertension, with GMRx2 superior to standard care protocol and achieving over 80% BP control from 1 month to end of follow-up